---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-003735"
form_type: "8-K"
ticker: "HOOK"
cik: "0001760542"
company_name: "HOOKIPA Pharma Inc."
filed_at: "2024-03-22T23:59:59+00:00"
generated_at: "2026-06-04T09:09:07.034957+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# HOOKIPA Pharma Q4/FY2023 net loss $24.8M/$81.6M; cash $117.5M; HB-200 ORR 42%

## Summary
- Net loss $24.8M (Q4) and $81.6M (FY2023), vs $12.3M and $64.9M in prior year.
- Revenue $7.4M (Q4) and $20.1M (FY2023); R&D expenses $21.2M and $86.4M.
- Cash and equivalents $117.5M at Dec 31, 2023, including $71M from capital raises and $15M in milestones.
- HB-200 + pembrolizumab showed 42% objective response rate in 1L HPV16+ HNSCC; pivotal trial to start 2024.
- Roche terminated HB-700 collaboration; HOOKIPA to regain rights; IND filing by April 2024 triggers final milestone.

## SEC filing metadata
- accession: 0001558370-24-003735
- form_type: 8-K
- ticker: HOOK
- cik: 0001760542
- company_name: HOOKIPA Pharma Inc.
- filed_at: 2024-03-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1760542/000155837024003735/0001558370-24-003735-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1760542/000155837024003735/hook-20240322x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-003735
- JSON: https://secwatch.observer/filing/0001558370-24-003735.json
- Plain text: https://secwatch.observer/filing/0001558370-24-003735.txt

## Key facts
- Earnings Releases
  HOOKIPA Pharma Inc. reported financial results for the fourth quarter and full year 2023.
  - Period: the fourth quarter and full year 2023
  - Result: reported results
  source text: On March 22, 2024, HOOKIPA Pharma Inc. (the “Company”) announced Financial Results for the Fourth Quarter and Full Year 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1760542/000155837024003735/0001558370-24-003735-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.